Novo, Lilly cut deal with Trump to lower prices of obesity drugs

BioPharma Dive Oncology | |

<figure><div><img src="https://imgproxy.divecdn.com/sK36taOntL0sw2_zWz8nSJ3873bo7plwtI6utL4RRlQ/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjQ1MzYyOTkyXzEuanBn.webp" /></div></figure><p>The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.</p>

Topics: oncology